Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)†

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

(2014) Luca Gianni et al.   LANCET ONCOLOGY

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

(2013) B. Gerber et al.   ANNALS OF ONCOLOGY

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)

(2013) Jens Huober et al.   EUROPEAN JOURNAL OF CANCER

Response-Guided Neoadjuvant Chemotherapy for Breast Cancer

(2013) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

(2012) Aimery de Gramont et al.   LANCET ONCOLOGY

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

(2012) Michael Untch et al.   LANCET ONCOLOGY

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

(2011) Manfred Kaufmann et al.   ANNALS OF SURGICAL ONCOLOGY

Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study

(2008) G. von Minckwitz et al.   JNCI-Journal of the National Cancer Institute

Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial

(2008) G. von Minckwitz et al.   JNCI-Journal of the National Cancer Institute